title: Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.
authors.affiliation: Westmead Cancer Care Centre, Westmead, New South Wales, Australia.
authors.forename: Katarzyna D
authors.initials: KD
authors.lastname: Chmiel
authors.forename: Dan
authors.initials: D
authors.lastname: Suan
authors.forename: Christopher
authors.initials: C
authors.lastname: Liddle
authors.forename: Brian
authors.initials: B
authors.lastname: Nankivell
authors.forename: Ramy
authors.initials: R
authors.lastname: Ibrahim
authors.forename: Charmaine
authors.initials: C
authors.lastname: Bautista
authors.forename: John
authors.initials: J
authors.lastname: Thompson
authors.forename: David
authors.initials: D
authors.lastname: Fulcher
authors.forename: Richard
authors.initials: R
authors.lastname: Kefford
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy*; D006801:Humans; D000074324:Ipilimumab; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D010976:Platelet Count; D015996:Survival Rate; D013601:T-Lymphocytes / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D000074324:Ipilimumab